F-18 sodium fluoride (NaF) PET/CT may be a valuable tool for imaging patients with psoriatic arthritis (PsA), as it reveals new bone formation in peripheral joints missed on clinical evaluation, according to a Dutch group.
"F-18 NaF PET/CT may be a novel clinically valuable tool to detect whole-body disease activity of PsA reflected by new bone formation in all disease domains of PsA, depicted in one scan," a team led by doctoral candidate Jerney de Jongh wrote. The study was published November 12 in the European Journal of Nuclear Medicine and Molecular Imaging.
PsA is a chronic and inflammatory musculoskeletal disease associated with psoriasis and several musculoskeletal manifestations, especially enthesitis, which is a painful inflammation at the site where tendons or ligaments attach to bone. Enthesitis activity in PsA can be accompanied by new bone formation.
Clinical assessment of enthesitis is challenging and has limited accuracy, as it is based only on the presence of tenderness and general soft tissue swelling, according to the authors. Moreover, other imaging approaches such as ultrasound and MRI have proven limited in identifying these sites, they wrote.
In this study, the researchers enrolled 16 patients with a clinical diagnosis of psoriatic arthritis from a rheumatology center at Amsterdam UMC. Patients underwent whole-body PET/CT scans 45 minutes after injection with F-18 NaF, a radiotracer that can identify new bone formation based on osteoblastic activity.
F-18 NaF enhancement in the right wrist and proximal interphalangeal joints of the hands (A), at the patella tendon insertion (B), in the metatarsophalangeal and interphalangeal joints of the feet and the right Achilles tendon (C), and in the distal interphalangeal joints of the hands (D). Image courtesy of the European Journal of Nuclear Medicine and Molecular Imaging.According to the study results, 81.8% of PET-positive joints were missed on clinical assessment. The team found that only 18.2% of PET-positive joints were clinically positive (that is, tender or swollen). But most PET-negative sites were also clinically negative (611/638). Similar results were found for entheses, with 70.5% of the PET-positive entheses missed on clinical evaluation and 29.5% of PET-positive entheses clinically identified.
De Jongh and colleagues acknowledged that their study cohort was small, and they urged further research.
"The clinical relevance of asymptomatic PET lesions in PsA should be further addressed in longitudinal studies, relating PET outcome with clinical and radiological follow-up over time," the investigators concluded.
